Hepatitis B Virus Infection Pipeline Insight Report 2024: Therapeutic Assessment of 80+ Companies and 90+ Drugs [Yahoo! Finance]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Yahoo! Finance
This "Hepatitis B Virus Infection - Pipeline Insight, 2024" report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Hepatitis B Virus Infection- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis B Virus Infection pipeline landscape is provided which includes the disease overview and Hepatitis B Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Hepatitis B Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed descripti
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology Appoints Jason O’Byrne as Chief Financial OfficerBusiness Wire
- Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell EngagersBusiness Wire
- Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.MarketBeat
- Research Bridge Partners Appoints New Members to the Company's Board of Directors [Yahoo! Finance]Yahoo! Finance
VIR
Earnings
- 8/1/24 - Miss
VIR
Sec Filings
- 9/10/24 - Form 4
- 9/10/24 - Form 8-K
- 9/9/24 - Form 144
- VIR's page on the SEC website